Analysts forecast that Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC – Get Rating) will report $78.29 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Tabula Rasa HealthCare’s earnings. The highest sales estimate is $92.10 million and the lowest is $67.21 million. Tabula Rasa HealthCare posted sales of $82.31 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 4.9%. The firm is scheduled to issue its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Tabula Rasa HealthCare will report full-year sales of $316.62 million for the current fiscal year, with estimates ranging from $278.03 million to $355.20 million. For the next financial year, analysts expect that the company will post sales of $355.59 million, with estimates ranging from $304.50 million to $423.70 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Tabula Rasa HealthCare.
Tabula Rasa HealthCare (NASDAQ:TRHC – Get Rating) last posted its quarterly earnings results on Thursday, February 24th. The company reported ($0.49) earnings per share (EPS) for the quarter. Tabula Rasa HealthCare had a negative return on equity of 84.40% and a negative net margin of 27.28%. The firm had revenue of $85.69 million for the quarter, compared to analysts’ expectations of $85.19 million. During the same period in the prior year, the company earned ($0.53) earnings per share. The company’s revenue for the quarter was up 11.2% on a year-over-year basis.
Shares of Tabula Rasa HealthCare stock opened at $2.30 on Friday. Tabula Rasa HealthCare has a 12-month low of $2.16 and a 12-month high of $53.38. The company has a current ratio of 3.79, a quick ratio of 3.73 and a debt-to-equity ratio of 10.40. The stock has a market cap of $59.46 million, a PE ratio of -0.62 and a beta of 1.55. The company has a 50-day moving average of $4.49 and a two-hundred day moving average of $9.08.
In other news, Director Gordon Tunstall bought 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 1st. The shares were purchased at an average price of $5.50 per share, for a total transaction of $55,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Dennis Helling bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, March 4th. The shares were purchased at an average price of $6.17 per share, for a total transaction of $30,850.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 17,000 shares of company stock worth $97,110. 10.20% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the business. Advisor Group Holdings Inc. boosted its holdings in shares of Tabula Rasa HealthCare by 19.6% in the 3rd quarter. Advisor Group Holdings Inc. now owns 6,006 shares of the company’s stock valued at $158,000 after purchasing an additional 983 shares during the last quarter. Public Sector Pension Investment Board boosted its holdings in shares of Tabula Rasa HealthCare by 4.3% in the 4th quarter. Public Sector Pension Investment Board now owns 48,196 shares of the company’s stock valued at $723,000 after purchasing an additional 2,000 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Tabula Rasa HealthCare by 3.8% in the 4th quarter. Rhumbline Advisers now owns 56,532 shares of the company’s stock valued at $848,000 after purchasing an additional 2,070 shares during the last quarter. Swiss National Bank boosted its holdings in shares of Tabula Rasa HealthCare by 4.4% in the 3rd quarter. Swiss National Bank now owns 52,100 shares of the company’s stock valued at $1,366,000 after purchasing an additional 2,200 shares during the last quarter. Finally, Masso Torrence Wealth Management Inc. acquired a new position in shares of Tabula Rasa HealthCare in the 4th quarter valued at $39,000. Institutional investors own 89.38% of the company’s stock.
About Tabula Rasa HealthCare (Get Rating)
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. The company operates in two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information; and MedWise medication therapy management software, a cloud-based platform designed to aid in the identification and resolution of medication and health-related problems.
- Get a free copy of the StockNews.com research report on Tabula Rasa HealthCare (TRHC)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.